topotecan has been researched along with Adenocarcinoma in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (33.33) | 18.2507 |
| 2000's | 19 (45.24) | 29.6817 |
| 2010's | 9 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Besterman, JM; Croom, DK; Emerson, DL; Evans, MG; Lackey, K; Leitner, PL; Luzzio, MJ; McIntyre, G; Sternbach, DD; Vuong, A; Yates, J | 1 |
| Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Beitinjaneh, A; Bliss, RL; Dudek, AZ; Kratzke, RA; Leach, J; Powell, SF; Tessema, M | 1 |
| Brewster, WR; Burger, RA; Gatcliffe, TA; Kuo, JV; Monk, BJ; Shah, A; Tewari, KS | 1 |
| Deslandres, M; Guillemet, C; Hardy-Bessard, AC; Kurtz, JE; Largillier, R; Lavau-Denes, S; Paraiso, D; Pujade-Lauraine, E; Roemer-Becuwe, C; Weber, B | 1 |
| Berros, JP; Blay, P; Coto, PP; Estrada, E; Fernandez, Y; Fra, J; Gonzalez, EE; Izquierdo, M; Jimenez, P; Lacave, AJ; Luque, M; Muñiz, I; Muriel, C; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Arase, H; Fukuoka, M; Ijima, T; Kudoh, S; Masuda, N; Matsui, K; Mukaiyama, A; Nakagawa, K; Negoro, S; Takada, M; Takeda, K; Yoshida, P | 1 |
| Brainerd, V; Chinnasami, B; Fain, J; Fidias, P; Heist, RS; Khan, W; Leopold, L; Lynch, TJ; Molina, JR; Sequist, LV; Temel, JS | 1 |
| Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z | 1 |
| Fusco, E; Lorusso, D; Mainenti, S; Malaguti, P; Masciullo, V; Pietragalla, A; Scambia, G | 1 |
| Belinsky, SA; Bernauer, AM; Dacic, S; Dahlberg, SE; Klinge, DM; Liu, Y; Schiller, JH; Siegfried, JM; Tessema, M; Thomas, CL; Yingling, CM | 1 |
| Glomme, S; Hertig, J; Hess, CF; Pradier, O; Rave-Fränk, M; Schmidberger, H; Virsik-Köpp, P; Weiss, E | 1 |
| Asmar, L; Garfield, DH; Gregurich, MA; Joppert, MG; Khandelwal, P; Marsland, TA; Nemunaitis, JJ | 1 |
| Aller, A; Andreotti, P; Caceres, G; Jiao, JA; Wong, H; Zankina, R; Zhu, X | 1 |
| Brafman, LB; Hershman, DL; Resnik, EE; Selleck, MJ; Shriberg, L; Smith, D; Tiersten, AD; Troxel, AB | 1 |
| Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA | 1 |
| Pavlidis, N; Pentheroudakis, G | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Davidson, NE; Gradishar, WJ; Kennedy, MJ; Lord, RS; O'Neill, A; Stewart, JA; Wolff, AC; Wood, WC | 1 |
| Carenini, N; Ciusani, E; Corna, E; Gatti, L; Perego, P; Zunino, F | 1 |
| AFlint, JA; Ardelt, B; Coradetti, T; Darzynkiewicz, Z; Davidowitz, H; Huang, Z; Lin, X; Mandecki, W; MKopacka, WM; Wang, Z | 1 |
| Grønlund, B | 1 |
| Bamias, A; Giannopoulos, A; Gourgoulis, G; Mountzios, G; Papaiakovou, EE; Rodolakis, A; Vlahos, G; Voulgaris, Z | 1 |
| Chen, TT; Escalon, J; Hills, D; Hochster, H; Ivy, P; Liebes, L; Lu, JM; Muggia, F; Sorich, J | 1 |
| Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
| Ara, G; Eder, JP; Herman, TS; Holden, SA; Korbut, T; Schwartz, GN; Teicher, BA | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM | 1 |
| Alexander, R; Amfoh, K; Engstrom, PF; Fox, S; Green, F; Kosierowski, R; Lusch, C; O'Dwyer, PJ; Raskay, B; Redei, I; Scher, RM | 1 |
| Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE | 1 |
| Balcerzak, SP; Benedetti, JK; Burris, HA; Macdonald, JS | 1 |
| Ansari, R; Bitran, JD; Fasanmade, AA; Fleming, GF; Hoffman, PC; Klepsch, A; Kugler, JW; Malone, D; Ratain, MJ; Vokes, EE | 1 |
| Broom, C; Fields, SZ; Fox, SC; Green, F; Kosierowski, R; Krebs, JB; O'Dwyer, PJ; Scher, RM; Simmonds, M; Stevenson, JP; Yao, KS | 1 |
| Bozec, L; Goldwasser, F; Misset, JL; Zeghari-Squalli, N | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Conrad, M; Jacobson, JL; Ketchel, SJ; Kuebler, JP; Macdonald, JS; Mills, G; Rivkin, S; Taylor, S; Weiss, G | 1 |
| Aguilar-Cordova, E; Hasenburg, A; Kaplan, A; Kaufman, RH; Kieback, CC; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW | 1 |
| Ampil, F; Bell, MC; Davidson, SA; Mathis, JM | 1 |
| Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Abbruzzese, JL; Anzai, H; Frost, P | 1 |
| Cheshire, PJ; Houghton, JA; Houghton, PJ; Myers, L; Stewart, CF; Synold, TW | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
3 review(s) available for topotecan and Adenocarcinoma
| Article | Year |
|---|---|
Management of leptomeningeal malignancy.
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Arachnoid Cysts; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Delayed-Action Preparations; Enzyme Inhibitors; Humans; Injections, Intravenous; Injections, Spinal; Leukemia; Lymphoma; Meningeal Neoplasms; Methotrexate; Palliative Care; Randomized Controlled Trials as Topic; Thiotepa; Topoisomerase I Inhibitors; Topotecan | 2005 |
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
22 trial(s) available for topotecan and Adenocarcinoma
| Article | Year |
|---|---|
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan | 2018 |
Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Topotecan | 2013 |
A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Survival Rate; Topotecan; Uterine Cervical Neoplasms | 2009 |
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Drug Synergism; Female; Humans; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2009 |
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prospective Studies; Survival; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2011 |
Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Survival Rate; Tissue Distribution; Topotecan; Treatment Outcome | 2010 |
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Resistance, Neoplasm; Female; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome | 2010 |
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan; Treatment Failure; Uterine Cervical Neoplasms | 2011 |
A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2003 |
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2004 |
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2004 |
Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193.
Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Breast Neoplasms; DNA Topoisomerases, Type I; Doxorubicin; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Middle Aged; Soft Tissue Neoplasms; Topotecan | 2005 |
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Topotecan; Treatment Outcome | 2008 |
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome | 1996 |
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Topotecan | 1996 |
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan; Tumor Cells, Cultured | 1996 |
Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Leukopenia; Male; Middle Aged; Stomach Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Regression Analysis; Topotecan; Treatment Outcome | 1998 |
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Topotecan; Treatment Outcome | 1998 |
A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Survival Analysis; Topotecan | 2000 |
Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer.
Topics: Acyclovir; Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenoviridae; Adult; Aged; Antiviral Agents; Combined Modality Therapy; Cystadenocarcinoma, Papillary; DNA; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polymerase Chain Reaction; Thymidine Kinase; Topotecan | 2000 |
Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Topotecan; Uterine Cervical Neoplasms | 2001 |
17 other study(ies) available for topotecan and Adenocarcinoma
| Article | Year |
|---|---|
Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Ovarian Neoplasms; Solubility; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water | 1996 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays | 2011 |
SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Cytokines; DNA Methylation; DNA Topoisomerases, Type I; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sulfatases; Sulfotransferases; Topoisomerase I Inhibitors; Topotecan; Ubiquitins | 2012 |
Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Cell Survival; Chromosome Aberrations; Colonic Neoplasms; Fibroblasts; Glioblastoma; Humans; Lymphocytes; Metaphase; Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topotecan; Tumor Cells, Cultured | 2002 |
Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Luciferases; Male; Mice; Prostatic Neoplasms; Topotecan; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Gene Silencing; Genetic Vectors; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transfection; Tumor Necrosis Factor-alpha; Up-Regulation | 2006 |
Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Transitional Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cost Control; Drug Screening Assays, Antitumor; Electronics; Humans; Lab-On-A-Chip Devices; Laser Scanning Cytometry; Lung Neoplasms; Microchip Analytical Procedures; Microscopy, Fluorescence; Mitoxantrone; Radio Waves; Ribonucleases; Topotecan | 2006 |
Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Topotecan | 2008 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Synergism; Female; Fibrosarcoma; Humans; Indazoles; Male; Mice; Mice, Inbred C3H; Novobiocin; Topotecan; Tumor Cells, Cultured | 1993 |
Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Division; DNA Damage; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Female; Half-Life; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays | 2002 |
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Colorectal Neoplasms; Decitabine; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Lethal Dose 50; Methylation; Mice; Mice, Inbred BALB C; Topotecan; Tumor Cells, Cultured | 1992 |
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Agents; Camptothecin; Child; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Osteosarcoma; Remission Induction; Rhabdomyosarcoma; Time Factors; Topotecan; Tumor Cells, Cultured | 1992 |